Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muslim, with type 2 diabetes mellitus~* Intends to fast during the month of Ramadan~* Hemoglobin A1c (HbA1c) ≤10% at screening~* On a stable dose of a SU drug (glibenclamide, glimepiride, or gliclazide), for at least three months, with or without metformin therapy at a stable dose~Exclusion Criteria:~* Type 1 diabetes mellitus~* Pregnant or breast feeding or with gestational diabetes~* Hypersensitivity or contraindication to dipeptidyl peptidase-4 (DPP-4) treatment~* Serum creatinine ≥1.5 mg/dL (males), ≥1.4 mg/dL (females)~* History of severe hypoglycemia (defined as a hypoglycemic event requiring the assistance of another individual, and/or resulting in a emergency department admission, physician office visit and/or hospitalization)~* Any use of insulin (prior to or during Ramadan)~* Use of any class of oral antidiabetic therapy other than an SU or metformin~* Current participation in another interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100mg taken orally once daily with or without metformin
- Sulfonylurea Therapy (Type: ACTIVE_COMPARATOR): Usual sulfonylurea therapy with or without metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).